HealthyXeLHCNCT05766384
Hyperpolarized 129Xe MRI Lung Health Cohort
An observational study of Healthy, run by University of Kansas Medical Center at 6 sites in United States.
Trial summary
A subset of young adults participating in the American Lung Association (ALA) Lung Health Cohort (LHC) will be imaged using Hyperpolarized 129Xe MRI to assess lung structure and function. Images will be used to improve the understanding of lung health and early lung abnormalities that may lead to chronic lung disease. Read more about this study
- Who is it for?
- Ages 25 to 35 years
- Conditions the study is for
- Healthy
- What is being tested?
- Hyperpolarized Xe129
- How many people
- 260 participants
- Where
- 6 sitesUnited States
- Study dates
- 30 Nov 2023to 31 Mar 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 35 years
- All sexes
- Adult
Study population: Participants enrolled in the Lung Health Cohort at participating Airways Clinical Research Centers. The investigators target to enroll approximately 50% females and enroll approximately 1/3 low socioeconomic status (SES) participants, 1/3 middle SES, and 1/3 high SES. The target for the population demographics is to match those of the larger, LHC parent study.
Who may be able to join
- Is enrolled in the American Lung Association Lung Health Cohort Study.
- Has completed CT imaging for the LHC study within 2 years of the scheduled Xe-MRI date.
Who cannot join
- Pacemaker, internal defibrillator or other implanted electronic devices or any standard MRI contraindications (e.g., claustrophobia, > 140 cm shoulder circumference, dependent on weight distribution).
- Is pregnant or breastfeeding
- Oxygen saturation (SpO2) <88% on room air or with supplemental oxygen.
Trial locations and contacts
6 sites in 1 country. Contact the study team or a site near you to ask about taking part.
6 sites in 1 country
United States6 sites, 6 recruiting
- Not yet recruiting
University of Illinois-Chicago
Chicago, Illinois, 60607
Debby Cogley, MPH, 312-996-9083, dcogley@uic.edu
- Recruiting
Duke University
Durham, North Carolina, 27708
Kaitlin Foy, 919-479-0861, Kaitlin Mae Foy <kaitlin.jones@duke.edu>
- Not yet recruiting
Baylor College of Medicine
Houston, Texas, 77030
Laura Bertrand, 713-798-4951, laura.bertrand@bcm.edu
- Not yet recruiting
MD Anderson Cancer Center
Houston, Texas, 77030
Jhankruti Desai, MPH, 877-632-6789, Jzaveri@mdanderson.org
- Recruiting
University of Iowa
Iowa City, Iowa, 52242
Eric Garcia, 319-384-8610, eric-garcia@uiowa.edu
- Recruiting
University of Kansas Medical Center
Kansas City, Kansas, 66160
Cristal Monge, 913-945-9399, chernandez@kumc.edu
About this study
Official title: Hyperpolarized 129Xe MRI to Identify Structural Determinants of Low Lung Function and Respiratory Symptoms in Young Adults From the Lung Health Cohort
A subset of young adults participating in the American Lung Association (ALA) Lung Health Cohort (LHC) will be imaged using Hyperpolarized 129Xe MRI to assess lung structure and function. Images will be used to improve the understanding of lung health and early lung abnormalities that may lead to chronic lung disease.
- Conditions
- Healthy
- Being tested
- Hyperpolarized Xe129
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hyperpolarized Xe129Drug
Also called Xenon, 129Xe, HP Xenon
Inhaled hyperpolarized 129Xe used as a signal agent for MRI of the lungs.
What is being measured
The primary outcome is the main question the study is designed to answer.
Xe-MRI Apparent Diffusion Coefficient
Correlation of Xe-MRI with FEV1/FVC and other measures of lung function
Measured: At baseline imaging timepoint
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Mar 2023
- Study start30 Nov 2023
- Primary completion31 Mar 2027 (estimated)
- Study completion31 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by University of Kansas Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 260 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Kansas Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- Johns Hopkins University, University of Iowa, Duke University, University of Illinois Chicago, Baylor College of Medicine, Temple University, University of Pennsylvania
- Responsible party
- Principal investigator, Peter J. Niedbalski, PhD, University of Kansas Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05766384
- Sponsor's protocol ID
- STUDY00160099
- Acronym
- XeLHC
- Status last verified
- Apr 2026
- First submitted
- 1 Mar 2023
- Last updated
- 1 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Deidentified imaging data will be made available to researchers by publishing on a data sharing site. Images will be made available upon completion of the study and publication of the summary paper.
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Hyperpolarized 129Xe MRI to Identify Structural Determinants of Low Lung Function and Respiratory Symptoms in Young Adults From the Lung Health Cohort
- ClinicalTrials.gov ID
- NCT05766384
- Acronym / sponsor ID
- XeLHC / STUDY00160099
- Conditions
- Healthy
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 260 participants (estimated)
- Lead sponsor
- University of Kansas Medical CenterUniversity, hospital or other
- Collaborators
- Johns Hopkins University, University of Iowa, Duke University, University of Illinois Chicago, Baylor College of Medicine, Temple University, University of Pennsylvania
- Study start
- 30 Nov 2023 (actual)
- Primary completion
- 31 Mar 2027 (estimated)
- Study completion
- 31 Mar 2027 (estimated)
- First posted
- 13 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A subset of young adults participating in the American Lung Association (ALA) Lung Health Cohort (LHC) will be imaged using Hyperpolarized 129Xe MRI to assess lung structure and function. Images will be used to improve the understanding of lung health and early lung abnormalities that may lead to chronic lung disease.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 25 to 35 years
- Sex
- All
- Age groups
- Adult
- Study population
- Participants enrolled in the Lung Health Cohort at participating Airways Clinical Research Centers. The investigators target to enroll approximately 50% females and enroll approximately 1/3 low socioeconomic status (SES) participants, 1/3 middle SES, and 1/3 high SES. The target for the population demographics is to match those of the larger, LHC parent study.
Key inclusion criteria (2 listed)
- Is enrolled in the American Lung Association Lung Health Cohort Study.
- Has completed CT imaging for the LHC study within 2 years of the scheduled Xe-MRI date.
Key exclusion criteria (3 listed)
- Pacemaker, internal defibrillator or other implanted electronic devices or any standard MRI contraindications (e.g., claustrophobia, > 140 cm shoulder circumference, dependent on weight distribution).
- Is pregnant or breastfeeding
- Oxygen saturation (SpO2) <88% on room air or with supplemental oxygen.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Hyperpolarized Xe129Also: Xenon, 129Xe, HP XenonInhaled hyperpolarized 129Xe used as a signal agent for MRI of the lungs. | Drug | – |
Primary outcome
Xe-MRI Apparent Diffusion Coefficient
Time frame: At baseline imaging timepoint
Correlation of Xe-MRI with FEV1/FVC and other measures of lung function
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2026.
- Individual participant dataSharing planned: Yes. Deidentified imaging data will be made available to researchers by publishing on a data sharing site. Images will be made available upon completion of the study and publication of the summary paper.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Healthy, run by University of Kansas Medical Center at 6 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Cristal Monge (913-945-9399, chernandez@kumc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Xe-MRI Apparent Diffusion Coefficient (time frame: At baseline imaging timepoint). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2026.